jueves, 29 de diciembre de 2016
Press Releases from NCI: Early-phase trial demonstrates shrinkage in pediatric neural tumors
Drug Shrinks Pediatric Neural Tumor - National Cancer Institute
12/27/2016 07:00 PM EST
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.